3 results
Demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the time to first occurrence of cardiovascular mortality and morbidity in subjects with T2DM and the clinical diagnosis of DKD.
Demonstrate whether, in addition to standard of care (SoC), finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to first occurrence of kidney failure, a sustained decrease of…
Primary:- The feasibility of SFR spectroscopy incorporated in an ERCP procedure.Secondary:- Determine physiological differences between benign and malignant biliary strictures, based on the obtained spectra acquired over a broad wavelength range (…